BC Innovations | Jun 11, 2015
Distillery Therapeutics

Therapeutics: Phosphoribosyl pyrophosphate synthetase 1 (PRPS1)

Cancer INDICATION: Acute lymphoblastic leukemia (ALL) In vitro studies suggest the purine synthesis inhibitor lometrexol could help treat thiopurine-resistant ALL. In ALL cells from 358 patients who relapsed after thiopurine therapy, whole-genome sequencing identified PRPS1...
BC Innovations | Jun 19, 2014
Cover Story

Breaking MYC metabolism

The metabolic enzyme phosphoribosyl pyrophosphate synthetase 2 could represent a tractable way to modulate the notoriously undruggable oncogene MYC. 1 The findings from a University of California, San Francisco team are licensed to Effector Therapeutics...
Items per page:
1 - 2 of 2